Starpharma announced that it has achieved marketing authorisation of the nasal spray product, VIRALEZETM, in Indonesia. Starpharma is in discussions with potential distribution partners in Indonesia and the successful registration will facilitate discussion with these parties. The Company is also continuing to progress regulatory and commercial activities in multiple other countries, including in markets across Southeast Asia.

VIRALEZETM is a nasal spray that is intended to physically trap and block cold/respiratory viruses in the nasal cavity. Multiple nonclinical studies have shown that VIRALEZETM traps and blocks a broad spectrum of respiratory viruses, including human coronaviruses, influenza viruses, rhinoviruses, and respiratory syncytial virus (RSV). VIRALEZETM nasal spray is now registered in more than 30 countries and is available in pharmacies, retail outlets and online in certain markets.